The high unmet medical need in the market has driven the R&D activities of vendors, thereby fueling the new therapies in the market. These new therapies are expected to be more helpful in overcoming the limitations of existing therapies namely the inability to treat the indication effectively.

PART 01: Executive summary

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

Highlights

PART 05: Disease overview

Understanding the disease

Pathophysiology

Central pathway

Peripheral pathway

Management of disease

PART 06: Pipeline analysis

PART 07: Market landscape

Global CINV drugs market

Five forces analysis

PART 08: Market segmentation by therapy

Serotonin receptor antagonists

NK1 receptor antoagonists

Others

PART 09: Geographical segmentation

CINV drugs market in Americas

CINV drugs market in EMEA

CINV drugs market in APAC

PART 10: Market drivers

Growing cancer population driving the market growth

Growing preference for chemotherapy drugs in

developing countries

Approval of new drugs fuels the market growth

PART 11: Impact of drivers

PART 12: Market challenges

Growing popularity of alternate therapies for the

treatment of cancer in developed countries

Loss of patent exclusivities increasing generic

competition

Limitations in existing therapies hindering the growth

prospects

PART 13: Impact of drivers and challenges

PART 14: Market trends

Robust R&D activities fueling the pipeline

Increasing inorganic growth strategies likely to fuel the

market growth

Novel treatment options coupled with new applications

PART 15: Vendor landscape

Competitive scenario

PART 16: Key vendor analysis

GlaxoSmithKline

Helsinn

Heron Therapeutics

Merck

Tesaro

Other prominent vendors

PART 17: Appendix

List of abbreviations

PART 18: Explore Technavio